Submission rejected on 20 March 2026 by Pythoncoder (talk). The subject is contrary to the purpose of Wikipedia. Rejected by Pythoncoder 2 months ago. Last edited by Pythoncoder 2 months ago. |  |
Submission declined on 6 January 2026 by Theroadislong (talk). This draft appears to contain text generated by a large language model (such as ChatGPT). You cannot use LLMs to generate article content.
Declined by Theroadislong 5 months ago.LLM-generated pages with certain obvious signs of being machine generated may be deleted without notice. These tools are prone to specific issues that violate our policies:
Instead, only summarize in your own words a range of independent, reliable, published sources that discuss the subject. See the advice page on large language models for more information. |  |
This draft is not adequately supported by reliable sources. Wikipedia's verifiability policy requires that all content be supported by reliable sources.
This draft's references do not show that the subject meets Wikipedia's criteria for inclusion for organizations and companies. The draft requires multiple published secondary sources that:
Declined by Dan arndt 6 months ago.
| |
Comment: Still shows signs of LLM use —pythoncoder (talk | contribs) 14:27, 20 March 2026 (UTC)
- Comment: In accordance with Wikipedia's Conflict of interest policy, I disclose that I have a conflict of interest regarding the subject of this article. Vysnia222 (talk) 13:50, 2 December 2025 (UTC)
Northway Biotech is a Lithuania-based contract development and manufacturing organization (CDMO) that provides services for protein-based biologics and gene therapy products. Northway Biotech operates facilities in Vilnius, Lithuania, and Waltham, Massachusetts, United States, supporting end-to-end services for cGMP (current Good Manufacturing Practice) manufacturing of biopharmaceuticals.[1][2] According to published reports, the company has worked with 90 clients across different types of therapies.[2]
Business activities
editNorthway Biotech provides contract development and manufacturing services for biopharmaceutical companies, focusing on protein-based biologics and gene therapies. Its activities include process development, analytical testing, and cGMP manufacturing of drug substances and drug products.[1][3] In 2021, Verslo žinios reported that Northway Biotech was involved in clinical-stage work related to the development of a coronavirus treatment, highlighting the company’s participation in applied biopharmaceutical research during the COVID-19 pandemic.[4] Northway Biotech was recognized as part of a group of companies contributing to the rapid expansion of Lithuania’s biotechnology sector over the past decade.[2]
History
editNorthway Biotech was established in 2004 in Vilnius, Lithuania, and the CEO and Chairman of the Board of Northway Biotech is Prof. Vladas Algirdas Bumelis.[5] In 2020, Northway Biotech expanded internationally by opening development and manufacturing laboratories in Waltham, Massachusetts. Business media described the move as strengthening the company’s presence in the United States and improving access to international clients.[5] In 2024, Northway Biotech expanded with a new facility in Vilnius, Lithuania, to include viral vector manufacturing platforms, and added viral clearance study services alongside its biologics manufacturing activities.[1]
Facilities
editReferences
edit- 1 2 3 "Northway Biotech Adds Gene Therapy CDMO Capabilities in Vilnius, Lithuania". Contract Pharma. 2024-10-22. Retrieved 19 March 2026.
- 1 2 3 4 "Lithuania branded as agile, punctual, overdelivering". PharmEdaily. 2025-09-17. Retrieved 19 March 2026.
- ↑ "Lithuania biotech pioneers look to build bridges with S. Korea". PharmEdaily. 2025-09-22. Retrieved 19 March 2026.
- ↑ "„Northway Biotech" atlieka vaisto nuo koronaviruso klinikinius tyrimus". 2021-05-07. Retrieved 19 March 2026.
- 1 2 3 "Bumelis apie gaminamus vaistus: suduria į minkštą vietą, jei veikia, valio – turtingi". LRT. 2025-12-16. Retrieved 19 March 2026.
- ↑ "Vilnius aims to become Europe's new biotech hub". NIB. 2024-05-23. Retrieved 19 March 2026.
- provide significant coverage: discuss the subject in detail, excluding routine coverage like product launches, staff appointments, or financial reports and listings in databases or listicles;
- are reliable: from reputable outlets with editorial oversight;
- are independent: not connected to the subject, such as press releases, the subject's own website, or sponsored content.
Please add references that meet all three of these criteria. If none exist, the subject is not yet suitable for Wikipedia.